What's Cooking at Microbix || Q2 2022 Investor Update
TSX: MBX | OTCQX: MBXBF CEO Cameron Groome, CFO Jim Currie, and COO Ken Hughes from Microbix ® join Deborah Honig for an in-depth update on the Company - from the growth they've seen this quarter to their upcoming plans for 2022. Microbix LATEST NEWS: https://microbix.com/news/ Microbix Investor Presentation: shorturl.at/vJKPR Microbix Website: https://microbix.com/ 0:00 - Introduction 0:58 - Q2 Updates 19:57 - Q&A Microbix develops proprietary biological and technology solutions for human health and well-being, with about 100 skilled employees and sales nearing C$ 2.0 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution S.p.A., Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc., and Thomas Scientific LLC. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. -- Website: https://adcap.ca/ Twitter: https://twitter.com/adelaide_cap LinkedIn: https://bit.ly/3FTfYoW Instagram: https://bit.ly/3v83ZyI Facebook: https://bit.ly/2XbXjDe Email: info@adcap.ca Adelaide Capital. A new IR strategy for a new market reality. Telling your story. Enabling your growth. Subscribe and get notified: https://bit.ly/3lALO1l Disclaimer: http://bit.ly/2A47b6g #Microbix #InvestorRelations #AdelaideCapital
TSX: MBX | OTCQX: MBXBF CEO Cameron Groome, CFO Jim Currie, and COO Ken Hughes from Microbix ® join Deborah Honig for an in-depth update on the Company - from the growth they've seen this quarter to their upcoming plans for 2022. Microbix LATEST NEWS: https://microbix.com/news/ Microbix Investor Presentation: shorturl.at/vJKPR Microbix Website: https://microbix.com/ 0:00 - Introduction 0:58 - Q2 Updates 19:57 - Q&A Microbix develops proprietary biological and technology solutions for human health and well-being, with about 100 skilled employees and sales nearing C$ 2.0 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution S.p.A., Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc., and Thomas Scientific LLC. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. -- Website: https://adcap.ca/ Twitter: https://twitter.com/adelaide_cap LinkedIn: https://bit.ly/3FTfYoW Instagram: https://bit.ly/3v83ZyI Facebook: https://bit.ly/2XbXjDe Email: info@adcap.ca Adelaide Capital. A new IR strategy for a new market reality. Telling your story. Enabling your growth. Subscribe and get notified: https://bit.ly/3lALO1l Disclaimer: http://bit.ly/2A47b6g #Microbix #InvestorRelations #AdelaideCapital